Cargando…

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Antibody–drug conjugates (ADCs) are a potential and promising therapy for a wide variety of cancers, including breast cancer. ADC-based drugs represent a rapidly growing field of breast cancer therapy. Various ADC drug therapies have progressed over the past decade and have generated diverse opportu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subhan, Md Abdus, Torchilin, Vladimir P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144345/ https://www.ncbi.nlm.nih.gov/pubmed/37111727 http://dx.doi.org/10.3390/pharmaceutics15041242

Ejemplares similares

Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
por: Subhan, Md Abdus, et al.
Publicado: (2021)

Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics
por: Subhan, Md Abdus
Publicado: (2022)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Hydrogels and Their Applications in Targeted Drug Delivery
por: Narayanaswamy, Radhika, et al.
Publicado: (2019)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
por: Palmerston Mendes, Livia, et al.
Publicado: (2017)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
por: Nader-Marta, Guilherme, et al.
Publicado: (2023)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
por: Yang, Tinglin, et al.
Publicado: (2023)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
por: Schettini, F., et al.
Publicado: (2021)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
por: Hoppenz, Paul, et al.
Publicado: (2020)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
por: Klute, Kelsey, et al.
Publicado: (2014)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0mo7dkikth9c3ene0ic3qr8e5m